Xerion Healthcare
Thame
About Xerion Healthcare
Xerion Healthcare develop nanoparticles that are used to improve treatment of cancer. The nanoparticles are injected into tumours just prior to standard radiotherapy and act to enhance the effectiveness of the treatment, amplifying the dose of free radicals generated by the X-rays. The nanoparticles are based on titanium dioxide, a common, non-toxic, semiconductor material. Xerion Healthcare are currently developing the treatment for head and neck and pancreatic tumours.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.4M
- Last round: Grant (Nov 2022)
- Website: xerionhealthcare.co.uk
- Phone: [email protected]
Industries & Categories
Health Care, Information Technology, Medical
Social Profiles
Canonical: https://fsome.com/organization/xerion-healthcare-161891 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.